Felzartamab + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Microvascular Inflammation
Conditions
Microvascular Inflammation
Trial Timeline
Jan 5, 2026 → Feb 10, 2028
NCT ID
NCT07219043About Felzartamab + Placebo
Felzartamab + Placebo is a phase 2 stage product being developed by Biogen for Microvascular Inflammation. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07219043. Target conditions include Microvascular Inflammation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07219043 | Phase 2 | Recruiting |
| NCT06935357 | Phase 3 | Recruiting |
| NCT06685757 | Phase 3 | Recruiting |
| NCT05021484 | Phase 2 | Completed |
Competing Products
7 competing products in Microvascular Inflammation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zibotentan + Placebo oral tablet | AstraZeneca | Phase 2 | 52 |
| Lercanidipine + Valsartan + Nicorandil + Doxazosin + Moxonidin + Pindolol + Amiloride, hydrochlorothiazide | Novartis | Pre-clinical | 23 |
| Ranolazine + Placebo | Gilead Sciences | Approved | 84 |
| Ranolazine + Placebo | Gilead Sciences | Phase 2 | 51 |
| Temanogrel + Placebo | Pfizer | Phase 2 | 51 |
| SAR247799 + Placebo + Sildenafil + Acetylcholine | Sanofi | Phase 1 | 32 |
| SAR407899 + Placebo + Adenosine + Regadenoson + 13N-ammonia + 82Rubidium | Sanofi | Phase 2 | 51 |